成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. JAK/STAT Signaling Stem Cell/Wnt
  3. STAT
  4. Napabucasin

Napabucasin  (Synonyms: BBI608)

目錄號: HY-13919 純度: 99.94%
COA 產品使用指南 技術支持

Napabucasin (BBI608) 是 STAT3 的抑制劑，抑制癌癥干細胞活性。

MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務

Napabucasin Chemical Structure

Napabucasin Chemical Structure

CAS No. : 83280-65-3

1.  客戶無需承擔相應的運輸費用。

2.  同一機構（單位）同一產品試用裝僅限申領一次，同一機構（單位）一年內

     可免費申領三個不同產品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥660
In-stock
1 mg ￥327
In-stock
5 mg ￥600
In-stock
10 mg ￥930
In-stock
50 mg ￥2880
In-stock
100 mg ￥3950
In-stock
200 mg ￥5190
In-stock
500 mg 詢價
1 g 詢價

* Please select Quantity before adding items.

Customer Review

    Napabucasin purchased from MCE. Usage Cited in: Cancer Med. 2016 Jun;5(6):1251-8.  [Abstract]

    Representative images of colony formation assay in PCa cell lines (PC-3 and 22RV1) and histological analysis of the colony number show that the colony formation of PCa cell lines are dramatically decreased after treated with 1 μM Napabucasin for 24 h.

    查看 STAT 亞型特異性產品:

    • 生物活性

    • 實驗參考方法

    • 純度 & 產品資料

    • 參考文獻

    生物活性

    Napabucasin (BBI608) is a STAT3 inhibitor which blocks stem cell activity in cancer cells.

    IC50 & Target[1]

    STAT3

     

    細胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    0.12 μM
    Compound: 6; BBI608
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay
    		[PMID: 32044231]
    A549 IC50
    0.74 μM
    Compound: Nap; BBI608
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 28558333]
    A549 IC50
    6.69 μM
    Compound: BBI608
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    		[PMID: 32631508]
    AGS IC50
    437 nM
    Compound: BBI608
    Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
    Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
    		[PMID: 36103247]
    BXPC-3 IC50
    1.3 μM
    Compound: NP
    Antiproliferative activity against human BxPC-3 cells harboring ZFP91siRNA assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human BxPC-3 cells harboring ZFP91siRNA assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33506674]
    BXPC-3 IC50
    1.4 μM
    Compound: NP
    Antiproliferative activity against human BxPC-3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against human BxPC-3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    		[PMID: 33506674]
    BXPC-3 IC50
    1.8 μM
    Compound: NP
    Antiproliferative activity against ZFP91 knockdown human BxPC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against ZFP91 knockdown human BxPC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33506674]
    BXPC-3 IC50
    1962 nM
    Compound: 1c; BBI608
    Inhibition of ATP production in human BXPC-3 cells incubated for 20 to 24 hrs by ATP assay kit method
    Inhibition of ATP production in human BXPC-3 cells incubated for 20 to 24 hrs by ATP assay kit method
    		[PMID: 36282975]
    BXPC-3 IC50
    5306 nM
    Compound: 1c; BBI608
    Anti-proliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay
    Anti-proliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay
    		[PMID: 36282975]
    Capan-2 IC50
    1586 nM
    Compound: 1c; BBI608
    Anti-proliferative activity against human Capan-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay
    Anti-proliferative activity against human Capan-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay
    		[PMID: 36282975]
    CT26 IC50
    2.5 μM
    Compound: Napabucasin
    Antiproliferative activity against mouse CT26 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse CT26 cells after 72 hrs by MTT assay
    		[PMID: 30472602]
    DU-145 IC50
    23.04 nM
    Compound: 3
    Anticancer activity against human DU145 cells after 72 hrs by XTT assay
    Anticancer activity against human DU145 cells after 72 hrs by XTT assay
    		[PMID: 18829316]
    HaCaT IC50
    0.5 μM
    Compound: 4a
    Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy
    Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy
    		[PMID: 22845014]
    HCT-116 IC50
    0.3 μM
    Compound: 87; BBI608
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 72 hrs by CellTiter-Glo assay
    		[PMID: 33445154]
    HEK293 IC50
    10.4 μM
    Compound: NP
    Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33506674]
    HepG2 IC50
    0.66 μM
    Compound: Nap; BBI608
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 28558333]
    HepG2 IC50
    0.84 μM
    Compound: BBI608
    Antiproliferative activity against human HepG2 cells overexpressed STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells overexpressed STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay
    		[PMID: 32603980]
    HepG2 IC50
    10.2 μM
    Compound: BBI 608
    Antiproliferative activity against human HepG2 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by CCK-8 assay
    		[PMID: 29604543]
    HepG2 IC50
    6.6 μM
    Compound: Napabucasin
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 30472602]
    HT-29 IC50
    0.14 μM
    Compound: BBI608
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    		[PMID: 32631508]
    HT-29 IC50
    1.6 μM
    Compound: Napabucasin
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 30472602]
    HUVEC IC50
    41.28 μM
    Compound: BBI608
    Antiproliferative activity against human HUVEC cells assessed as inhibition of cell growth in measured after 72 hrs by MTT assay
    Antiproliferative activity against human HUVEC cells assessed as inhibition of cell growth in measured after 72 hrs by MTT assay
    		[PMID: 34435487]
    K562 IC50
    1 μM
    Compound: 6
    Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay
    		[PMID: 30003778]
    L02 IC50
    18.7 μM
    Compound: BBI 608
    Antiproliferative activity against human L02 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human L02 cells after 48 hrs by CCK-8 assay
    		[PMID: 29604543]
    MCF-10A IC50
    0.54 μM
    Compound: BBI608
    Cytotoxicity against human MCF10A cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    Cytotoxicity against human MCF10A cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    		[PMID: 32631508]
    MCF7 IC50
    < 1 μM
    Compound: 6; BBI608
    Inhibition of IL-6 induced STAT3 phosphorylation at Tyr705 residue in human MCF7 cells preincubated for 1 hr followed by IL-6 stimulation and measured after 1 hr by Western blot analysis
    Inhibition of IL-6 induced STAT3 phosphorylation at Tyr705 residue in human MCF7 cells preincubated for 1 hr followed by IL-6 stimulation and measured after 1 hr by Western blot analysis
    		[PMID: 32044231]
    MCF7 IC50
    0.24 μM
    Compound: 6; BBI608
    Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay
    		[PMID: 32044231]
    MCF7 IC50
    0.63 μM
    Compound: BBI608
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    		[PMID: 32631508]
    MCF7 EC50
    1.49 μM
    Compound: BBI-608
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CyQuant assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CyQuant assay
    		[PMID: 33352047]
    MCF7 IC50
    11.42 μM
    Compound: BBI608
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34435487]
    MDA-MB-231 IC50
    0.25 μM
    Compound: 6; BBI608
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay
    		[PMID: 32044231]
    MDA-MB-231 IC50
    0.34 μM
    Compound: Nap; BBI608
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 28558333]
    MDA-MB-231 IC50
    0.7 μM
    Compound: BBI608
    Antiproliferative activity against human MDA-MB-231 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay
    Antiproliferative activity against human MDA-MB-231 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay
    		[PMID: 32603980]
    MDA-MB-231 IC50
    1.29 μM
    Compound: BBI608
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs MTT assay
    		[PMID: 32631508]
    MDA-MB-231 EC50
    1.8 μM
    Compound: BBI-608
    Antiproliferative activity against human MDA-MB-231 cells harbouring STAT3 assessed as reduction in cell viability at upto 10 uM incubated for 72 hrs by CyQuant assay
    Antiproliferative activity against human MDA-MB-231 cells harbouring STAT3 assessed as reduction in cell viability at upto 10 uM incubated for 72 hrs by CyQuant assay
    		[PMID: 33352047]
    MDA-MB-231 IC50
    10.97 μM
    Compound: BBI608
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34435487]
    MDA-MB-231 IC50
    2.1 μM
    Compound: 6
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    		[PMID: 30003778]
    MDA-MB-231 IC50
    9.68 μM
    Compound: BBI608
    Antiproliferative activity against human drug tolerant MDA-MB-231/lapatinib cells assessed as inhibition of cell growth in measured after 72 hrs by MTT assay
    Antiproliferative activity against human drug tolerant MDA-MB-231/lapatinib cells assessed as inhibition of cell growth in measured after 72 hrs by MTT assay
    		[PMID: 34435487]
    MDA-MB-468 IC50
    1.14 μM
    Compound: 1; BBI608
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell growth measured after 48 hrs by CCK8 assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell growth measured after 48 hrs by CCK8 assay
    		[PMID: 33126089]
    MDA-MB-468 IC50
    1.14 μM
    Compound: BBI608
    Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay
    Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay
    		[PMID: 32603980]
    MGC-803 IC50
    871.8 nM
    Compound: BBI608
    Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
    Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
    		[PMID: 36103247]
    MIA PaCa-2 IC50
    1.2 μM
    Compound: NP
    Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    		[PMID: 33506674]
    MKN-45 IC50
    3943 nM
    Compound: BBI608
    Antiproliferative activity against human MKN-45 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
    Antiproliferative activity against human MKN-45 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
    		[PMID: 36103247]
    PC-3 IC50
    5.25 μM
    Compound: Napabucasin
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 30472602]
    U-251 IC50
    2.6 μM
    Compound: Napabucasin
    Antiproliferative activity against human U251 cells after 72 hrs by MTT assay
    Antiproliferative activity against human U251 cells after 72 hrs by MTT assay
    		[PMID: 30472602]
    體外研究
    (In Vitro)

    Napabucasin 抑制干性標志物的表達，并殺死從除 PCa 外的幾種腫瘤中分離出的高干性癌細胞。Napabucasin不僅抑制PCa細胞的細胞增殖、細胞運動、細胞存活、集落形成能力和致瘤潛能，增加細胞凋亡和對多西紫杉醇的敏感性，還能有效阻斷PrCSCs的球體形成并殺死它們，同時抑制干性基因表達。Napabucasin 在 48、72、96 和 120 h 時抑制 PC-3 細胞和 22RV1 細胞的細胞增殖 (P<0.05)。細胞運動和集落形成能力與腫瘤轉移過程密切相關。Napabucasin 顯著降低體外PCa 細胞系的集落形成和細胞運動能力 (P<0.05)。與對照組相比，1 μM Napabucasin處理PC-3和22RV1細胞的增殖從第2天到第5天顯著降低 (P<0.05)[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內研究
    (In Vivo)

    與 PBS 相比，Napabucasin (40 mg/kg) 或 Docetaxel 顯著降低異種移植腫瘤的生長和腫瘤體積 (TV) (P<0.05)。值得注意的是，雖然在 PC-3 小鼠異種移植模型中 Napabucasin 組和多西紫杉醇組之間沒有觀察到差異，但在 22RV1 小鼠異種移植模型中 Napabucasin 組的 TV 甚至低于多西紫杉醇組 (P<0.05)。此外，與 PBS 相比，Napabucasin 或多西他賽也能顯著降低腫瘤重量 (P<0.05)[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    240.21

    Formula

    C14H8O4
    CAS 號
    性狀

    固體

    顏色

    Light yellow to green yellow

    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性數(shù)據(jù)
    細胞實驗： 

    DMSO 中的溶解度 : 4.44 mg/mL (18.48 mM; 超聲助溶; 吸濕的 DMSO 對產品的溶解度有顯著影響，請使用新開封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制儲備液
    濃度 溶劑體積 質量 1 mg 5 mg 10 mg
    1 mM 4.1630 mL 20.8151 mL 41.6302 mL
    5 mM 0.8326 mL 4.1630 mL 8.3260 mL
    查看完整儲備液配制表

    * 請根據(jù)產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。
    儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內使用， -20°C儲存時，請在1年內使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 0.5 mg/mL (2.08 mM); 懸濁液; 超聲助溶

      此方案可獲得 0.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

      以 1 mL 工作液為例，取 100 μL 5.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 0.5 mg/mL (2.08 mM); 懸濁液; 超聲助溶

      此方案可獲得 0.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

      以 1 mL 工作液為例，取 100 μL 5.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術支持聯(lián)系。
    動物實驗體內工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產品資料

    純度: 99.94%

    參考文獻
    Cell Assay
    [1]

    The antiproliferative activity of Napabucasin against the PCa cell lines PC-3 and 22RV1 is examined. For cell proliferation assay, the PCa cell lines (22RV1 and PC-3) are seeded in 96-well plates at 2×103 cells/well in a final volume of 100 μL and incubated overnight. The proliferation of PC-3 and 22RV1 cells treated with 1 μM Napabucasin. The viability of cells is determined with CellTiter 96 non-radioactive cell proliferation assay (MTS). For colony formation assay, cells are placed in a six-well plate and maintained in RPMI-1640 supplemented with 10% FBS for 2 weeks. The colonies are fixed with 4% paraformaldehyde, stained with 0.1% crystal violet and counted[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Mice[1]
    A total of 1×106 PC-3 cells or 8×106 22RV1 cells in 100 μL of PBS are injected subcutaneously into dorsal flanks of an immunodeficient nude mouse. The animals are treated i.p. with Napabucasin (40 mg/kg), Docetaxel (10 mg/kg), or PBS q3d once the tumors have reached 50 mm3. The tumor volume (TV) is calculated every 4 days according to the following standard formula: TV (mm3)=length×width2×0.5.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻

    完整儲備液配制表

    * 請根據(jù)產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。
    儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內使用， -20°C儲存時，請在1年內使用。

    可選溶劑 濃度 溶劑體積 質量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.1630 mL 20.8151 mL 41.6302 mL 104.0756 mL
    5 mM 0.8326 mL 4.1630 mL 8.3260 mL 20.8151 mL
    10 mM 0.4163 mL 2.0815 mL 4.1630 mL 10.4076 mL
    15 mM 0.2775 mL 1.3877 mL 2.7753 mL 6.9384 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產品:

    Your information is safe with us. * Required Fields.

       產品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產品名稱：
    Napabucasin
    目錄號：
    HY-13919
    需求量：